1887

Abstract

It is well known that anti-prion protein (PrP) monoclonal antibodies (mAbs) inhibit abnormal isoform PrP (PrP) formation in cell culture. Additionally, passive immunization of anti-PrP mAbs protects the animals from prion infection via peripheral challenge when mAbs are administered simultaneously or soon after prion inoculation. Thus, anti-PrP mAbs are candidates for the treatment of prion diseases. However, the effects of mAbs on disease progression in the middle and late stages of the disease remain unclear. This study carried out intraventricular infusion of mAbs into prion-infected mice before and after clinical onset to assess their ability to delay disease progression. A 4-week infusion of anti-PrP mAbs initiated at 120 days post-inoculation (p.i.), which is just after clinical onset, reduced PrP levels to 70–80 % of those found in mice treated with a negative-control mAb. Spongiform changes, microglial activation and astrogliosis in the hippocampus and thalamus appeared milder in mice treated with anti-PrP mAbs than in those treated with a negative-control mAb. Treatment with anti-PrP mAb prolonged the survival of mice infected with Chandler or Obihiro strain when infusion was initiated at 60 days p.i., at which point PrP is detectable in the brain. In contrast, infusion initiated after clinical onset prolonged the survival time by about 8 % only in mice infected with the Chandler strain. Although the effects on survival varied for different prion strains, the anti-PrP mAb could partly prevent disease progression, even after clinical onset, suggesting immunotherapy as a candidate for treatment of prion diseases.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83578-0
2008-06-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/6/1533.html?itemId=/content/journal/jgv/10.1099/vir.0.83578-0&mimeType=html&fmt=ahah

References

  1. Bate, C., Reid, S. & Williams, A. ( 2001; ). Killing of prion-damaged neurones by microglia. Neuroreport 12, 2589–2594.[CrossRef]
    [Google Scholar]
  2. Bate, C., Boshuizen, R. S., Langeveld, J. P. & Williams, A. ( 2002; ). Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport 13, 1695–1700.[CrossRef]
    [Google Scholar]
  3. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C. & Aguzzi, A. ( 1996; ). Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339–343.[CrossRef]
    [Google Scholar]
  4. Check, E. ( 2002; ). Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462
    [Google Scholar]
  5. Chesebro, B., Race, R. & Kercher, L. ( 2005; ). Scrapie pathogenesis in brain and retina: effects of prion protein expression in neurons and astrocytes. J Neurovirol 11, 476–480.[CrossRef]
    [Google Scholar]
  6. Demaimay, R., Adjou, K. T., Beringue, V., Demart, S., Lasmézas, C. I., Deslys, J. P., Seman, M. & Dormont, D. ( 1997; ). Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol 71, 9685–9689.
    [Google Scholar]
  7. Doh-ura, K., Ishikawa, K., Murakami-Kubo, I., Sasaki, K., Mohri, S., Race, R. & Iwaki, T. ( 2004; ). Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78, 4999–5006.[CrossRef]
    [Google Scholar]
  8. Donofrio, G., Heppner, F. L., Polymenidou, M., Musahl, C. & Aguzzi, A. ( 2005; ). Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 79, 8330–8338.[CrossRef]
    [Google Scholar]
  9. Ehlers, B. & Diringer, H. ( 1984; ). Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65, 1325–1330.[CrossRef]
    [Google Scholar]
  10. El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C. & Luster, A. D. ( 2007; ). Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13, 432–438.[CrossRef]
    [Google Scholar]
  11. Enari, M., Flechsig, E. & Weissmann, C. ( 2001; ). Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98, 9295–9299.[CrossRef]
    [Google Scholar]
  12. Farquhar, C. F. & Dickinson, A. G. ( 1986; ). Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 67, 463–473.[CrossRef]
    [Google Scholar]
  13. Feraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Creminon, C., Vilette, D., Lehmann, S. & Grassi, J. ( 2005; ). Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 280, 11247–11258.[CrossRef]
    [Google Scholar]
  14. Fernandez-Borges, N., Brun, A., Whitton, J. L., Parra, B., Diaz-San Segundo, F., Salguero, F. J., Torres, J. M. & Rodriguez, F. ( 2006; ). DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 80, 9970–9976.[CrossRef]
    [Google Scholar]
  15. Furuoka, H., Yabuzoe, A., Horiuchi, M., Tagawa, Y., Yokoyama, T., Yamakawa, Y., Shinagawa, M. & Sata, T. ( 2005; ). Effective antigen-retrieval method for immunohistochemical detection of abnormal isoform of prion proteins in animals. Acta Neuropathol 109, 263–271.[CrossRef]
    [Google Scholar]
  16. Gilch, S., Wopfner, F., Renner-Muller, I., Kremmer, E., Bauer, C., Wolf, E., Brem, G., Groschup, M. H. & Schatzl, H. M. ( 2003; ). Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 278, 18524–18531.[CrossRef]
    [Google Scholar]
  17. Goñi, F., Knudsen, E., Schreiber, F., Scholtzova, H., Pankiewicz, J., Carp, R., Meeker, H. C., Rubenstein, R., Brown, D. R. & other authors ( 2005; ). Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413–421.[CrossRef]
    [Google Scholar]
  18. Heppner, F. L., Musahl, C., Arrighi, I., Klein, M. A., Rülicke, T., Oesch, B., Zinkernagel, R. M., Kalinke, U. & Aguzzi, A. ( 2001; ). Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178–182.[CrossRef]
    [Google Scholar]
  19. Horiuchi, M. & Caughey, B. ( 1999; ). Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 18, 3193–3203.[CrossRef]
    [Google Scholar]
  20. Horiuchi, M., Yamazaki, N., Ikeda, T., Ishiguro, N. & Shinagawa, M. ( 1995; ). A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 76, 2583–2587.[CrossRef]
    [Google Scholar]
  21. Horiuchi, M., Mochizuki, M., Ishiguro, N., Nagasawa, H. & Shinagawa, M. ( 1997; ). Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. J Vet Med Sci 59, 133–136.[CrossRef]
    [Google Scholar]
  22. Kaneko, K., Peretz, D., Pan, K. M., Blochberger, T. C., Wille, H., Gabizon, R., Griffith, O. H., Cohen, F. E., Baldwin, M. A. & Prusiner, S. B. ( 1995; ). Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci U S A 92, 11160–11164.[CrossRef]
    [Google Scholar]
  23. Kim, C. L., Umetani, A., Matsui, T., Ishiguro, N., Shinagawa, M. & Horiuchi, M. ( 2004a; ). Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320, 40–51.[CrossRef]
    [Google Scholar]
  24. Kim, C. L., Karino, A., Ishiguro, N., Shinagawa, M., Sato, M. & Horiuchi, M. ( 2004b; ). Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 85, 3473–3482.[CrossRef]
    [Google Scholar]
  25. Kocisko, D. A., Caughey, W. S., Race, R. E., Roper, G., Caughey, B. & Morrey, J. D. ( 2006; ). A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother 50, 759–761.[CrossRef]
    [Google Scholar]
  26. Kuwata, K., Nishida, N., Matsumoto, T., Kamatari, Y. O., Hosokawa-Muto, J., Kodama, K., Nakamura, H. K., Kimura, K., Kawasaki, M. & other authors ( 2007; ). Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104, 11921–11926.[CrossRef]
    [Google Scholar]
  27. Ladogana, A., Casaccia, P., Ingrosso, L., Cibati, M., Salvatore, M., Xi, Y. G., Masullo, C. & Pocchiari, M. ( 1992; ). Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 73, 661–665.[CrossRef]
    [Google Scholar]
  28. Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P. C., Brandner, S. & Collinge, J. ( 2003; ). Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302, 871–874.[CrossRef]
    [Google Scholar]
  29. Marella, M., Gaggioli, C., Batoz, M., Deckert, M., Tartare-Deckert, S. & Chabry, J. ( 2005; ). Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment. J Biol Chem 280, 1529–1534.[CrossRef]
    [Google Scholar]
  30. Morrissey, M. P. & Shakhnovich, E. I. ( 1999; ). Evidence for the role of PrPC helix 1 in the hydrophilic seeding of prion aggregates. Proc Natl Acad Sci U S A 96, 11293–11298.[CrossRef]
    [Google Scholar]
  31. Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. ( 2003; ). Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9, 448–452.[CrossRef]
    [Google Scholar]
  32. Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L. & other authors ( 2003; ). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46–54.[CrossRef]
    [Google Scholar]
  33. Paxinos, G. & Franklin, K. B. J. ( 2001; ). The Mouse Brain in Stereotaxic Coordinates, 2nd edn. San Diego: Academic Press.
  34. Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulm, G., Mehlhorn, I. R., Legname, G., Wormald, M. R. & other authors ( 2001; ). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739–743.[CrossRef]
    [Google Scholar]
  35. Perrier, V., Solassol, J., Crozet, C., Frobert, Y., Mourton-Gilles, C., Grassi, J. & Lehmann, S. ( 2004; ). Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 89, 454–463.[CrossRef]
    [Google Scholar]
  36. Priola, S. A., Raines, A. & Caughey, W. S. ( 2000; ). Porphyrin and phthalocyanine antiscrapie compounds. Science 287, 1503–1506.[CrossRef]
    [Google Scholar]
  37. Rainov, N. G., Tsuboi, Y., Krolak-Salmon, P., Vighetto, A. & Doh-Ura, K. ( 2007; ). Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 7, 713–726.[CrossRef]
    [Google Scholar]
  38. Sadowski, M. & Wisniewski, T. ( 2004; ). Vaccines for conformational disorders. Expert Rev Vaccines 3, 279–290.[CrossRef]
    [Google Scholar]
  39. Schenk, D. ( 2002; ). Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3, 824–828.
    [Google Scholar]
  40. Schwarz, A., Krätke, O., Burwinkel, M., Riemer, C., Schultz, J., Henklein, P., Bamme, T. & Baier, M. ( 2003; ). Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 350, 187–189.[CrossRef]
    [Google Scholar]
  41. Sigurdsson, E. M., Brown, D. R., Daniels, M., Kascsak, R. J., Kascsak, R., Carp, R., Meeker, H. C., Frangione, B. & Wisniewski, T. ( 2002; ). Immunization delays the onset of prion disease in mice. Am J Pathol 161, 13–17.[CrossRef]
    [Google Scholar]
  42. Solforosi, L., Criado, J. R., McGavern, D. B., Wirz, S., Sánchez-Alavez, M., Sugama, S., DeGiorgio, L. A., Volpe, B. T., Wiseman, E. & other authors ( 2004; ). Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514–1516.[CrossRef]
    [Google Scholar]
  43. Speare, J. O., Rush, T. S., III, Bloom, M. E. & Caughey, B. ( 2003; ). The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein. J Biol Chem 278, 12522–12529.[CrossRef]
    [Google Scholar]
  44. Todd, N. V., Morrow, J., Doh-ura, K., Dealler, S., O'Hare, S., Farling, P., Duddy, M. & Rainov, N. G. ( 2005; ). Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt–Jakob disease. J Infect 50, 394–396.[CrossRef]
    [Google Scholar]
  45. Trevitt, C. R. & Collinge, J. ( 2006; ). A systematic review of prion therapeutics in experimental models. Brain 129, 2241–2265.[CrossRef]
    [Google Scholar]
  46. Uryu, M., Karino, A., Kamihara, Y. & Horiuchi, M. ( 2007; ). Characterization of prion susceptibility in Neuro2a mouse neuroblastoma cell subclones. Microbiol Immunol 51, 661–667.[CrossRef]
    [Google Scholar]
  47. White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J. & Hawke, S. ( 2003; ). Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80–83.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83578-0
Loading
/content/journal/jgv/10.1099/vir.0.83578-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error